BMO Capital: 'Centessa Pharmaceuticals (CNTA) Remains One of Our Favorite Names in 2025'
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $35.00 price target on Centessa Pharmaceuticals (NASDAQ: CNTA).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
